New trial data has cemented Club holding Eli Lilly 's pole position in the highly competitive obesity drug race. The news Eli Lilly's obesity drug Zepbound bested its main rival Wegovy — made by Denmark's Novo Nordisk — in the first head-to-head trial comparing the fast-growing weight loss treatments. Shares of Eli Lilly, a longtime portfolio name, rose more than 2.5% Wednesday, to around $833 apiece. LLY YTD mountain Eli Lilly YTD "I think [Lilly stock] should return to the $900 level," Jim Cramer said Wednesday on the Morning Meeting. A sign with the company logo sits outside of the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana.

---

Persons: Eli Lilly, Eli, Zepbound, Wegovy —, Zepound, Lilly, Wegovy, Leerink, Ozempic, Lilly's, Biden, Donald Trump, Robert F, Kennedy Jr, Eli Lilly YTD, Jim Cramer, Dave Ricks, Mounjaro, Jim Cramer's, Jim, Scott Olson Organizations: Denmark's Novo Nordisk —, Novo Nordisk, Analysts, Drug, FDA, Morning, CNBC, Company, Getty Locations: Eli Lilly's, Indianapolis , Indiana